Are combined oral contraceptive pills (BCP) contraindicated in patients with a history of deep vein thrombosis (DVT), and do medical abortion medications (mifepristone and misoprostol) increase the risk of DVT?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Combined Oral Contraceptives Are Absolutely Contraindicated in Patients with a History of DVT; Abortion Pills Do Not Increase DVT Risk

Combined estrogen-progestin contraceptives (BCPs) are formally contraindicated in women with a personal history of deep vein thrombosis or pulmonary embolism 1. In contrast, medical abortion medications (mifepristone and misoprostol) have no established association with venous thromboembolism and are not contraindicated in patients with DVT history.

Combined Oral Contraceptives and DVT History

Absolute Contraindication

The French Society of Endocrinology guidelines explicitly state that combined estrogen-progestin contraception is formally contraindicated in women with a personal history of thromboembolic disease 1. This applies to all routes of combined hormonal contraception, including pills, patches, and vaginal rings 1.

The mechanism is clear: combined hormonal contraceptives significantly increase VTE risk by modifying circulating antithrombin and protein S levels, increasing resistance to activated protein C, and affecting multiple clotting parameters 1. Women with a personal history of DVT or PE already have demonstrated thrombotic tendency, and adding estrogen-containing contraceptives multiplies this baseline risk by factors of 5-16 when inherited thrombophilia is present 1.

Safe Alternatives for Women with DVT History

If hormonal contraception is desired after a DVT event:

  • First-line options: Progestin-only methods (microdose or macrodose) 1
  • Specific safe options: Levonorgestrel IUD, desogestrel 75 mcg, norethisterone 350 mg 1
  • Evidence base: These progestin-only methods show no significant increase in VTE risk (OR: 0.61 for levonorgestrel IUD, 95% CI 0.24-1.53) 2

The 2020 American College of Rheumatology guidelines strongly recommend IUDs (levonorgestrel or copper) or progestin-only pills in women with positive antiphospholipid antibodies, a similar high-risk thrombotic population 2.

Important caveat: Injectable medroxyprogesterone acetate (DMPA/Depo-Provera) should be avoided even though it's progestin-only, as studies suggest increased VTE risk (RR 2.67,95% CI 1.29-5.53) 2.

Abortion Medications and DVT Risk

No Established Thrombotic Risk

Medical abortion medications—mifepristone and misoprostol—have no documented association with venous thromboembolism. The FDA drug labels for these medications do not list DVT or thrombosis as contraindications or warnings 3, 4.

Mifepristone's contraindications include pregnancy (for its Cushing's syndrome indication), drug interactions with CYP3A substrates, and vaginal bleeding disorders—but notably not thrombotic conditions 3. Similarly, misoprostol's primary concerns relate to uterine effects and pregnancy complications, not thrombosis 4.

The 2025 Society of Family Planning guidelines on medication abortion between 14-27 weeks gestation make no mention of thrombotic risk or DVT as a contraindication 5. This comprehensive guideline addresses safety extensively but does not identify VTE as a concern with mifepristone-misoprostol regimens.

Mechanism Explains Safety

This safety profile makes pharmacologic sense: abortion medications work through progesterone receptor antagonism (mifepristone) and prostaglandin-mediated uterine contraction (misoprostol), neither of which affects coagulation pathways. Unlike combined oral contraceptives that contain estrogen—the component responsible for prothrombotic effects—abortion pills contain no estrogen and therefore lack the mechanism to increase VTE risk.

Clinical Algorithm for Contraception After DVT

For women with documented DVT history:

  1. Discontinue immediately if currently on combined hormonal contraception 1
  2. Replace with barrier methods during acute phase with access to emergency contraception 1
  3. Transition to progestin-only contraception once stable:
    • Best choice: Levonorgestrel IUD (most effective, no VTE risk increase) 2
    • Alternative: Copper IUD (non-hormonal, highly effective) 2
    • If IUD declined: Progestin-only pill (desogestrel 75 mcg or norethisterone 350 mg) 1
  4. Avoid: All combined estrogen-progestin methods, DMPA injection 2, 1

For women needing abortion with DVT history:

  • Medical abortion with mifepristone-misoprostol is not contraindicated
  • Procedural abortion is also safe
  • Choice should be based on patient preference, gestational age, and other clinical factors—not thrombotic history

Common Pitfalls to Avoid

Do not screen routinely for thrombophilia before prescribing contraception; limit testing to women with first-degree family history of VTE before age 60 1. If testing is indicated, include PT, aPTT, antithrombin, protein C, protein S, factor V Leiden, and prothrombin FII 20210A 1.

Superficial venous thrombosis does not contraindicate hormonal contraception 1—this is a critical distinction from deep vein thrombosis.

Family history alone (first-degree relative with VTE before age 60) is only a relative contraindication to combined contraceptives, making progestin-only methods the preferred first-line choice 1.

References

Related Questions

Can a 27-year-old non-smoking woman with a BMI of 40, two children (youngest 3 years old), and no personal or family history of deep vein thrombosis or pulmonary embolism safely start combined oral contraceptive pills?
I am taking an ethinylestradiol‑containing combined oral contraceptive and now have calf cramps while walking (previously only at rest) plus intermittent chest pain when lying down; could this indicate deep‑vein thrombosis or pulmonary embolism, and should I stop the estrogen‑containing pill?
Can combined Oral Contraceptive Pills (OCPs) be prescribed to a patient with a history of pre-eclampsia?
What measures can be taken to prevent deep vein thrombosis in an 11-year-old patient taking combined oral contraceptives for prolonged menstrual bleeding?
Are Aurovela (norethindrone acetate/ethinyl estradiol) and Feirza similar oral contraceptive pills?
What is the recommended evaluation and management for an elderly patient with a suspected umbilical hernia?
How should I taper Tobradex (tobramycin 0.3% and dexamethasone 0.1%) eye drops in a patient who develops intense ocular redness when reducing to twice daily?
What is the optimal blood pressure management for a patient taking hydrochlorothiazide 25 mg who has hyperuricemia (uric acid 9 mg/dL)?
Does elevated serum creatinine cause kidney damage?
Does melatonin cause a decrease in heart rate?
Would a computed tomography (CT) scan demonstrate a distal biceps tendon rupture?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.